🔬 Swiss vaccine developer LimmaTech Biologics AG has been awarded a $2.2m grant from CARB-X to advance its hexavalent vaccine targeting Neisseria gonorrheae, a priority bacterial pathogen. 💉 The vaccine candidates have shown promise in overcoming the bacteria’s immune evasion mechanisms and could help fight antimicrobial resistance. 🔬 Gonorrhea is a common sexually transmitted bacterial infection that affects millions of people worldwide. The grant will support the development of a cost-effective vaccine to protect patients in low- and middle-income countries.
📢 Swiss Vaccine Developer Receives $22m Grant to Fight Gonorrhea and Antimicrobial Resistance
Introduction:
Swiss multivalent vaccine developer LimmaTech Biologics AG has received a US$2.2 million grant from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Main points:
- LimmaTech will use the grant to advance preclinical development of its hexavalent vaccine candidate for Neisseria gonorrhoeae.
- The vaccine candidates have shown effectiveness in overcoming the bacteria’s natural immune evasion mechanisms, which helps restrict the increase of antimicrobial resistance (AMR).
- Neisseria gonorrhoeae is recognized as a Priority Bacterial Pathogen by the WHO, and gonorrhea is the second most commonly reported sexually-transmitted bacterial infection globally.
- The goal of CARB-X is to support the development of a cost-effective vaccine that can protect patients in low- and middle-income countries where affordability is crucial.
- CARB-X has successfully supported the advancement of several projects in the antibiotic pipeline and has recently received support from the Novo Nordisk Foundation.
Conclusion:
LimmaTech Biologics has received a significant grant from CARB-X to advance the development of a hexavalent vaccine candidate for Neisseria gonorrhoeae. This vaccine has the potential to address the increasing antimicrobial resistance associated with gonorrhea and protect patients in low- and middle-income countries. The support from CARB-X is crucial for advancing the development of new vaccines and combating antibiotic resistance.
